Artelo Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.8M
- Price
- $3.37
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.17%
- Volume
- 27.2K
About
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Quick stats
Shares outstanding547.8K
Computed float—
Float / sharesUnknown
Cash runway (months)0.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001621221
Websitehttps://www.artelobio.com
AI Summary
AI-generated1/24
minorbullishoperations update
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Artelo Biosciences was selected for its first-ever company presentation at BIO-Europe 2026, to be delivered by CSO Andrew Yates on November 10 in Cologne.
The presentation will recap previously reported ART26.12 data, including favorable Phase 1 safety and pharmacokinetics and nonclinical efficacy in peripheral neuropathy and osteoarthritis models.
Management frames the slot as a partnering opportunity to attract potential licensees across its pain, cancer cachexia, and obesity programs; no deal or new clinical data was announced.